Reactions 1680, p210 - 2 Dec 2017 Elevated lipid levels following off-label use: case report In a retrospective study consisting of 40 patients (aged 1-17 years), a patient [age and sex not stated] was described who developed elevated lipid levels after receiving off-label dose of lopinavir/ritonavir [route and dosage not stated]. The patient, who had a history of HIV-1 infection, was receiving lopinavir/ritonavir twice a day. Later, the patient was switched to lopinavir/ritonavir once a day. Subsequently, the patient presented with constantly elevated lipid levels. The highest measured level of triglyceride was 7.8 mmol/L and cholesterol was 9.4 mmol/L. Lopinavir/ritonavir was discontinued [duration of treatment to reaction onset and outcome not stated]. Author comment: "One child stopped treatment because of persistent elevated lipid levels, with highest measured cholesterol of 9.4 mmol/L and triglycerides of 7.8 mmol/L." "Intolerability is mostly reported in treatment-naive children. In our study, lipid profiles remained stable and within the normal range in most children." "[Lopinavir/ritonavir] is approved to be used BID only in children, and once-daily use is therefore considered off-label." Gondrie IPE, et al. Sustained Viral Suppression in HIV-infected Children on Once- daily Lopinavir/Ritonavir in Clinical Practice. Pediatric Infectious Disease Journal 36: 976-980, No. 10, Oct 2017. Available from: URL: http://doi.org/10.1097/ INF.0000000000001627 - Netherlands 803286040 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud